Hormonal, Metabolic, and Signaling Interactions in PAH (NCT01884051)
Hormonal, Metabolic, and Signaling Interaction in Pulmonary Arterial Hypertension
🩺 Plain-English Summary (8th-Grade Level)
Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences of the disease.
Who can join: Review the eligibility criteria below.
Location: Vanderbilt University Medical Center — Nashville, Tennessee
Age range: Not specified to 90 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Vanderbilt University Medical Center — Nashville, Tennessee
📞 Contact the Study Coordinator
Phone: (800) 288-0378
Email: Kelly.Burke@vumc.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Idiopathic Pulmonary Arterial Hypertension
- Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH) — Nashville, Tennessee
- Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals — Nashville, Tennessee
Explore by condition: All Idiopathic Pulmonary Arterial Hypertension clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.